Managing the Impact of Immunogenicity in an Era of Immunotherapy: From Bench to Bedside.
Anti-drug antibody
Antibody
Clinical trial
Immune response
Immunogenicity
Immunotherapy
Therapeutic drug monitoring
Journal
Journal of pharmaceutical sciences
ISSN: 1520-6017
Titre abrégé: J Pharm Sci
Pays: United States
ID NLM: 2985195R
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
26
01
2021
revised:
27
03
2021
accepted:
30
03
2021
pubmed:
5
4
2021
medline:
5
8
2021
entrez:
4
4
2021
Statut:
ppublish
Résumé
Biotherapeutics have revolutionized our ability to treat life-threatening diseases. Despite clinical success, the use of biotherapeutics has sometimes been limited by the immune response mounted against them in the form of anti-drug antibodies (ADAs). The multifactorial nature of immunogenicity has prevented a standardized approach for assessing this and each of the assessment methods developed so far does not exhibit high enough reliability to be used alone, due to limited predictiveness. This prompted the Roche Pharma Research and Early Development (pRED) Immunogenicity Working Group to establish an internal preclinical immunogenicity toolbox of in vitro/in vivo approaches and accompanying guidelines for a harmonized assessment and management of immunogenicity in early development. In this article, the complex factors influencing immunogenicity and their associated clinical ramifications are discussed to highlight the importance of an end-to-end approach conducted from lead optimization to clinical candidate selection. We then examine the impact of the resulting lead candidate categorization on the design and implementation of a multi-tiered ADA/immunogenicity assay strategy prior to phase I (entry into human) through early clinical development. Ultimately, the Immunogenicity Toolbox ensures that Roche pRED teams are equipped to address immunogenicity in a standardized manner, paving the way for lifesaving products with improved safety and efficacy.
Identifiants
pubmed: 33812888
pii: S0022-3549(21)00196-9
doi: 10.1016/j.xphs.2021.03.027
pii:
doi:
Substances chimiques
Antibodies
0
Immunologic Factors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2575-2584Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declarations of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: the following authors (KBF, KH, GS, CMD, JB, MFF, KGS, CS, TS, AD) declare to be paid employees of Roche Pharmaceutical Research and Early Development. NC declares to be a paid employee of F. Hoffmann-La Roche AG.